WhiteLab Genomics Secured €23.2 Million Series B
The biotech firm plans to scale its AI-driven genomic medicine platform following a successful funding round.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Do you believe AI-driven technologies will significantly improve the effectiveness of medical treatments?
WhiteLab Genomics has closed a €23.2 million ($26 million) Series B funding round led by AVP. The Paris-based firm intends to use the capital to accelerate its AI-driven drug design and expand in vivo validation capabilities.
Why it matters
This investment provides the resources necessary to scale the company's proprietary ALFRED platform, which designs and optimizes genetic payloads. The move reflects a broader industry push to integrate artificial intelligence into the development of genomic medicines.
The company utilizes its proprietary ALFRED platform to design and optimize delivery vehicles and genetic payloads. The platform integrates experimental validation and in vivo testing to streamline the drug design cycle.
The players
WhiteLab Genomics
This biotechnology company focuses on the development of AI-driven genomic medicine.
AVP
This investment firm led the Series B round and manages €2.5 billion in assets.
François Robinet
He was appointed to the Board of Directors at WhiteLab Genomics.
Daniel Teper
He was appointed to the Board of Directors at WhiteLab Genomics.
The details
Founded in 2019, WhiteLab Genomics maintains operations across Paris, Boston, and Montreal. The firm plans to utilize this new capital to expand its in vivo validation work to include synthetic promoters and non-viral delivery technologies.
Timeline
WhiteLab Genomics was founded in 2019.
The funding round was announced on October 6, 2026.
The Tech Race
This development marks a significant milestone for the ALFRED drug design platform as it competes in the evolving sector of AI-powered genetic engineering. The firm's expansion follows a trajectory of increasing reliance on computational biology to replace slower traditional drug design cycles.
The investment accelerates the development timeline for new genetic therapies, potentially reaching clinical applications sooner. Users and patients should monitor these technological advancements as the firm scales its validation work for non-viral delivery systems.
The takeaway
The successful funding round positions the firm to bridge the gap between AI-driven design and physical in vivo testing. This expansion highlights the critical importance of scaling laboratory validation capacity in modern drug development.
Further reading
Explore the broader Biotech industry landscape for more insights into AI-driven drug development.
Live Poll
Do you believe AI-driven technologies will significantly improve the effectiveness of medical treatments?
